PIPERACILLIN TAZOBACTAM - FRESENIUS 4 G0.5 G Israel - English - Ministry of Health

piperacillin tazobactam - fresenius 4 g0.5 g

neopharm (israel) 1996 ltd - piperacillin as sodium salt; tazobactam as sodium salt - powder for solution for infusion - piperacillin as sodium salt 4.0 g/vial; tazobactam as sodium salt 0.5 g/vial - tazobactam - - treatment of systemic and/or local infections caused by susceptible organisms.- piperacillin/tazobactam in combination with an aminoglycoside is indicated for the treatment of suspected bacterial infections in neutropenic adults and children above 2 years. - appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.

REVLIMID 2.5 MG Israel - English - Ministry of Health

revlimid 2.5 mg

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 2.5 mg - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

REVLIMID 2.5 MG Israel - English - Ministry of Health

revlimid 2.5 mg

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 2.5 mg - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

REVLIMID 20 MG Israel - English - Ministry of Health

revlimid 20 mg

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 20 mg - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

REVLIMID 20 MG Israel - English - Ministry of Health

revlimid 20 mg

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 20 mg - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

REVLIMID 7.5 MG Israel - English - Ministry of Health

revlimid 7.5 mg

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 7.5 mg - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

REVLIMID 7.5 MG Israel - English - Ministry of Health

revlimid 7.5 mg

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 7.5 mg - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

SODIUM CHLORIDE VIOSER SOLUTION 0.9 % Israel - English - Ministry of Health

sodium chloride vioser solution 0.9 %

eldan electronic instruments co ltd, israel - sodium chloride - solution - sodium chloride 9 mg/ml - sodium chloride - short- term intravascular volume substitution. hypotonic dehydration or isotonic dehydration. vehicle solution for supplementary medication.flued and electrolyte replacement, hypochloremic alkalosis and chloride losses.externally for wound irrigation and moistening of wound tamponades dressing

DEXTROSE VIOSER SOLUTION FOR INFUSION 5 % Israel - English - Ministry of Health

dextrose vioser solution for infusion 5 %

eldan electronic instruments co ltd, israel - dextrose anhydrous - solution for infusion - dextrose anhydrous 5 % - vehicle solution for supplementary medication. energy supply, hypertonic dehydration

RINGER LACTATED SOLUTIONVIOSER Israel - English - Ministry of Health

ringer lactated solutionvioser

eldan electronic instruments co ltd, israel - calcium chloride dihydrate; potassium chloride; sodium chloride; sodium lactate - solution for infusion - sodium lactate 3.14 g/l; calcium chloride dihydrate 0.26 g/l; potassium chloride 0.41 g/l; sodium chloride 6.02 g/l - electrolytes - source of water and electrolytes. regulation or maintenance of metabolic acidosis (except lactic acidosis)